Two Ongoing Clinical Trials of IPI-145 for Hematologic Malignancies
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.
DUO
- DUO is a randomized, phase III trial comparing IPI-145 to ofatumumab for patients with relapsed or refractory CLL or SLL.
- Ofatumumab is a CD20-directed cytolytic monoclonal antibody approved for the treatment of CLL.
- Patients in this trial are randomized 1:1 and are able to cross over.
DYNAMO
- DYNAMO is a single-arm, phase II trial of patients with non-Hodgkin lymphoma that are no longer responding to rituximab or chemotherapy.
- There is currently no established therapy for this group of patients.
<<<
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
